Double Moving Average Crossover
|Bid||9.63 x 900|
|Ask||9.75 x 800|
|Day's Range||8.82 - 9.80|
|52 Week Range||0.38 - 13.07|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||1.70|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Subscribe to Yahoo Finance Plus to view Fair Value for AMAM
SAN DIEGO, March 13, 2023--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares ("ADSs") pursuant to the Company’s at-the-market ("ATM") program established on Aug 5, 2022, through Cowen and Company LLC ("TD Cowen"), acting as sales agent. The ATM program had an aggregate offering price of up to $80 million in gross proceeds. Through the utilization of the ATM, the Company has raised $78 million in
After getting a bump on Monday for its switch to the Nasdaq Stock Market, there was a bit of a correction.
SAN DIEGO, March 06, 2023--Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx’s American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol "AMAM".